Randolph's World

A groundbreaking cancer vaccine called ELI-002 2P has shown extraordinary promise against pancreatic and colorectal cancers, two of the deadliest forms of cancer. Unlike personalized vaccines, ELI-002 2P is an “off-the-shelf” therapy targeting KRAS mutations, which drive 93% of pancreatic and 50% of colorectal cases. In a trial of 25 patients recovering from surgery, 84% developed KRAS-specific T cells, with nearly one-quarter experiencing complete tumor clearance. Among the strongest responders, most remained cancer-free nearly 20 months later, far exceeding typical survival outcomes. By targeting lymph nodes directly, the vaccine primes the immune system to prevent recurrence offering a potentially accessible, cost-effective, and powerful new tool in cancer care. Larger trials are now underway to confirm its impact.